AllDocs -> cancers

07. Gastrointestinal Cancer including Liver OP169 COMBINATION ANALYSIS OF ACTIVATOR PROTEIN-1 FAMILY MEMBERS, SP1AND AN ACTIVATOR PROTEIN-2 ? -RELATED FACTOR BINDING TO DIFFERENT REGIONS OF THE UROKINASE RECEPTOR (U-PAR) GENE IN RESECTED COLORECTAL CANCERS Schewe, D. 1 ; Biller, T. 2 ; Maurer, G. 3 ; Assangani, I. 2 ; Leupold, J. 2 ; Lengyel, E. 4 ; Post, S. 5 ; Allgayer, H. 2 1 Dr. von Haunersches Kinderspital, Ludwig-Maximilians-Universität, München; 2 Abteilung für experimentelle Chirurgie und Molekulare Onkologie, Universitätsklinikum, Mannheim; 3 Chirurgische Klinik Grosshadern, Ludwig-Maximilians-Universität, München; 4 Department of Obstetrics and Gynecology, University ...

07. Gastrointestinal Cancer including Liver OP168 EGFR REACTIVATES TELOMERASE IN IMMORTALIZED SQUAMOUS EPITHELIAL CELLS THROUGH PI3K/AKT-MEDIATED PHOSPHORYLATION AND TRANSCRIPTIONAL REGULATION VIA HIF-1ALPHA Heeg, S. 1 ; Heeg, S. 1 ; von Werder, A. 1 ; Doebele , M. 1 ; Quante, M. 1 ; Scheffer, E. 1 ; Goessel, G. 1 ; Fulda, C. 1 ; Kunert , H. 1 ; Nakagawa, H. 2 ; Beijersbergen, R. 3 ; Blum, H.E. 1 1 Medizinische Klinik, Universität, Freiburg; 2 Gastroenterology Division, University of Pennsylvania, Philadelphia, PA, USA; 3 Netherlands Cancer Center, Amsterdam, Netherlands Introduction: In our cellular model ...

07. Gastrointestinal Cancer including Liver OP171 ROLE OF SRC-FAMILY KINASES IN GASTROINTESTINAL STROMAL TUMORS Bauer, S. 1 ; Demetri, G.D. 3 ; Fletcher, J.A. 2 1 Westdeutsches Tumorzentrum, Universitätsklinikum, Essen; 2 Brigham & Womens Hospital, Harvard Medical School, Boston, MA, USA; 3 Dana Farber Cancer Institute, Boston, MA, USA Background: Inhibition of KIT oncoproteins by imatinib mesylate (IM) induces clinical responses in most GIST patients. However, many patients develop IM-resistance due to secondary KIT mutations and none of the novel KIT inhibitors inhibits all known IM-resistance mutations. Src-family kinases (SFK) are important signaling intermediates in related kinase-driven tumor models (ALL, CML) and dual-specific Src/Abl-inhibitors show promising activity in IM-resistant CML ...

07. Gastrointestinal Cancer including Liver OP172 DEVELOPMENT OF THE NOVEL DOUBLE ENRICHED NESTED PCR (DEN-PCR) ASSAY FOR DETECTION OF K-RAS CODON 12 MUTATIONS IN COLORECTAL CARCINOMA PATIENTS Kraus, M.C. 1 ; Berger, M.R. 1 1 Deutsches Krebsforschungszentrum (DKFZ), Heidelberg Detection of disseminated tumour cells (DTC) in histopathologically inconspicuous tissues is presumably of high importance but often flawed with the difficulty to discover one mutated cell in a surplus of wild-type cells. The aim of this study was to develop a rapid and sensitive assay for detecting K-ras codon 12 mutations indicating DTC in tissue samples from colorectal carcinoma patients. Methods: The double enriched nested (DEN-) PCR makes use of the thermostable restriction enzyme BstNI during the first PCR and locked nucleic acid (LNA) clamping oligonucleotides during the second ...

CBA714-Test slide, Liver cancer tissues with corresponding normal tissues (formalin fixed) For research use only Specifications: • No. of cases: 6 • Tissue type: Test slide, Liver cancer tissues with corresponding normal tissues • No. of spots: 6 spots from each cancer case (6 spots) 6 non-neoplastic spots (6 spots) •Total spots: 12 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 with corresponding normal tissues (formalin fixed) For research use only Summary of tissue spots No Sex Age Key word 1 A 1 m 67 Liver : hepatocellular carcinoma 2 B 1 ...

447 March Road Kanata, Ontario Canada K2K 1X8 Tel: 613 592-2790 NEWS RELEASE March 21, 2000 Inoperable Primary Liver Cancer Treatment Receives Humanitarian Device Exemption TheraSphere’s Microscopic Glass Beads Offer Alternative to Chemotherapy in Inoperable Cases Kanata, Ontario, Canada - MDS Nordion, a global leader in radioisotope technology, received authorization from the US Food and Drug Administration to market TheraSphere ® , a non-surgical outpatient therapy that uses microscopic glass beads to deliver radiation therapy to treat inoperable hepatocellular carcinoma (HCC), a liver cancer . This form of liver cancer is one of the most common tumours in the world, affecting up to 10 percent of the population in sub-Saharan Africa and Southeast Asia. 1 At present, the incidence of HCC in the US is low, but is expected to increase due to a ...

Spatiotemporal Density Feature Analysis to Detect Liver Cancer from Abdominal CT Angiography Yoshito Mekada 1 , Yuki Wakida 2 , Yuichiro Hayashi 2 , Ichiro Ide 2 , and Hiroshi Murase 2 1 School of Life System Science and Technology, Chukyo University, 101 Tokodachi Kaizu Toyota, 470-0393, Japan y-mekada@life.chukyo-u.ac.jp http://www.st.chukyo-u.ac.jp/y-mekada/ 2 Graduate School of Information Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603, Japan yhayashi@suenaga.m.is.nagoya-u.ac.jp, ide@is.nagoya-u.ac.jp, murase@is.nagoya-u.ac.jp Abstract. In this paper, we propose a method of detecting liver can- cers from dynamic X-ray computed tomography (CT) images based on a two-dimensional histogram analysis. In the diagnosis of a liver , a doc- tor examines dynamic ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN LIVER CANCER TISSUE ARRAY Catalog Number: TMA-121 Each dot represents a DISEASED tissue spot from one individual specimen that was selected and pathologically confirmed ( Liver carcinoma tissue array) Cases: 63 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: PCNA confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 E ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN LIVER CANCER TISSUE ARRAY Catalog Number: TMA-122 Each dot represents a DISEASED tissue spot from one individual specimen that was selected and pathologically confirmed ( Liver carcinoma tissue array) Cases: 63 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: PCNA confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 E ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN LIVER CANCER TISSUE ARRAY Catalog Number: TMA-126 Each three (3) dots from three different tissue spots represents one single specimen that was selected and pathologically confirmed (Hepatocellular carcinoma tissue array) Cases: 22 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: AFP confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN LIVER CANCER TISSUE ARRAY Catalog Number: TMA-125 Each three (3) dots from three different tissue spots represents one single specimen that was selected and pathologically confirmed (Hepatocellular carcinoma tissue array) Cases: 21 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: PCNA confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN LIVER CANCER TISSUE ARRAY Catalog Number: TMA-123 This is a COMBINATION ARRAY PANEL from diseased, normal and adjacent (1.5cm) to specimen that was selected and pathologically confirmed ( Liver carcinoma tissue array) Cases: 42 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: PCNA confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN LIVER CANCER TISSUE ARRAY Catalog Number: TMA-124 Each three (3) dots from three different tissue spots represents one single specimen that was selected and pathologically confirmed (Normal liver tissue array) Cases: 20 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: PCNA confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN LIVER CANCER TISSUE ARRAY Catalog Number: TMA-127 Each dot represents a DISEASED tissue spot from one individual specimen that was selected and pathologically confirmed (Hepatocellular carcinoma tissue array) Cases: 63 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: AFP confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN LIVER CANCER TISSUE ARRAY Catalog Number: TMA-120 Each dot represents a DISEASED tissue spot from one individual specimen that was selected and pathologically confirmed ( Liver carcinoma tissue array) Cases: 80 Cores: 80 Diameter: 1.5mm Thickness: 5 µm Standard IHC: Anti-proliferating cell nuclear antigen (PCNA) antibody confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 D ...

PRIMARY CANCER OF THE LIVER MEDICAL APPENDIX (including hepatoma, hepatocellular carcinoma) DEFINITION 1. Cancer is a term which embraces a large number of different diseases, the common feature of which is a malignant tumour. This is a growth (neoplasm) which is not circumscribed but which infiltrates the surrounding tissues and metastasises (spreads to other sites in the body, thereby producing secondary deposits). Any tissue in the body may be affected. 2. Cancers are classified according to the tissue of origin. Carcinoma arises from epithelial tissue and sarcoma from connective tissue. The suffix - blastoma implies a tumour of embryonic origin. 3. Cancer of the liver is a malignant tumour of the liver . It may arise from the liver cells (hepatocytes), from the bile duct epithelium or from the supporting mesenchymal tissue. Hepatocellular carcinoma (or hepatoma), ...

INTRODUCTION The liver is the most common site of recur- rence after potentially curative surgery for colorectal cancer [6]. In general, ultrasonog- raphy (US) and computed tomography (CT) are used for the detection of liver metastasis [11]. Positron emission tomography (PET) using 18 F-fluorodeoxyglucose (FDG) is now available as a diagnostic tool and is used suc- cessfully in the diagnosis of various cancers [12, 13, 14]. In this retrospective study, we compared this new imaging technique with US and CT in the detection of liver metasta- sis in patients with recurrent colorectal can- cer, and we discussed the utility of PET in the diagnosis of liver metastasis from col- orectal cancer . SUBJECTS AND METHODS Among colorectal survey patients who underwent whole-body FDG PET in our institution between September 1994 and May 1997, eight were finally ...

14. Donor and Recipient Tumor Data OPTN/SRTR 2005 Annual Report __ 14-10 Table 14.7 History of Cancer among Deceased Liver Donors 1995 to 2004 „ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ† ‚ ‚ Year of Transplant ‚ ‚ ‡ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ‰ ‚ ‚ 1995 ‚ 1996 ‚ 1997 ‚ 1998 ‚ 1999 ‚ 2000 ‚ 2001 ‚ 2002 ‚ 2003 ‚ 2004 ‚ ‡ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒ‰ ‚ Total Transplants ‚ 60‚ 61‚ 82‚ 86‚ 89‚ 96‚ 96‚ 98‚ 133‚ 141‚ ‡ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒ‰ ‚ Type of Cancer ‚ ‚ ‚ ‚ ‚ ‚ ‚ ...

Contact: Diane Shnitzler or Emily Oehler (703) 691-1805 November 28-Dec 1: Emily Oehler, (703) 801-7790 Diane Shnitzler, (571) 276-8480 Embargoed for Release, November 28, 2005 Week-Long Symposium on Minimally Invasive Cancer Treatments for Liver , Kidney, Bone and Lung, and Emerging Research Society of Interventional Radiology Foundation and RSNA Convene Multi-Disciplinary Oncology Meeting in the Clinical and Basic Science of Interventional Oncology Chicago, IL (November 28, 2005) – Clinicians and basic scientists from academia, private practice, government and industry come together today for a week-long multi-disciplinary symposium in interventional oncology, a rapidly growing area of medicine involving minimally invasive interventional radiology treatments for cancer . The first two days of the meeting focus on treatments for liver , kidney, bone ...

81 ©2005, Institute of Oncology Sremska Kamenica, Serbia and Montenegro Archive of Oncology 2005;13 Suppl 1:81. Zoran PETROVI Dino TARABAR Nebojpa MANOJLOVI Rajko DODER DEPARTMENT OF GASTROINTESTINAL ONCOLOGY, CLINIC FOR GASTROENTEROLOGY, MMA, BELGRADE, SERBIA AND MONTENEGRO EGFR expression in liver metastases in patients with colorectal cancer EGFR positive primary tumor and response to systemic chemotherapy and targeted therapy Conference abstract UDC: 616.36-006:616.348-006:616.351-006:615-085 KEYWORDS: Receptor,Epidermal Growth Factor; ColorectalNeoplasms; Neoplasm Metastasis –ore ARGIROVI CLINIC OF UROLOGY, DIVISION OF UROLOGIC CHEMOTHERAPY, CLINICAL CENTER OF SERBIA, BELGRADE, SERBIA AND MONTENEGRO Does retroperitoneal lymphadenectomy represent the best treatment option in patients with clinical stage A of nonseminomatous testicular ...

• LIVER CANCER • Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats Bing Tan, Jie-Fei Huang, Qun Wei, Hong Zhang, Run-Zhou Ni ELSEVIER PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(38):5938-5943 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2005 The WJG Press and Elsevier Inc. All rights reserved. Bing Tan, Jie-Fei Huang, Qun Wei, Hong Zhang, Run-Zhou Ni, Department of Digestive Medicine, Affiliated Hospital of Nantong Medical College, Nantong 226001, Jiangsu Province, China Co-first-authors: Bing Tan Correspondence to: Dr. Jie-Fei Huang, Department of Digestive Medicine, Affiliated Hospital of Nantong Medical College, Nantong 226001, Jiangsu Province, China Telephone: +86-513-5806629 Received: 2004-06-08 Accepted: ...

• LIVER CANCER • Inhibitory effects of N-(4-hydrophenyl) retinamide on liver cancer and malignant melanoma cells Xing-Zhong Wu, Li Zhang, Bi-Zhi Shi, Ping Hu ELSEVIER PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(37):5763-5769 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2005 The WJG Press and Elsevier Inc. All rights reserved. Xing-Zhong Wu, Li Zhang, Bi-Zhi Shi, Ping Hu, Department of Biochemistry and Molecular Biology, Shanghai Medical College, Fudan University, Shanghai 200032, China Supported by the National Natural Science Foundation of China, No. 30070183 and 30470398 Correspondence to: Professor Xing-Zhong Wu, MD, PhD, Department of Biochemistry and Molecular Biology, Shanghai Medical College, Fudan University, Shanghai 200032, China. xz_wu@shmu.edu.cn ...

26 Dartmouth Medicine ternal beam radiation. The Y-90 decays over 2.7 days into non-ra- dioactive zirconium, and the tiny bits of by-then inert glass stay in the liver , causing no problems. Patients who have had Therasphere have suffered mini- mal side effects, and their tumors have decreased substantially in size. Zaki says it is a very good al- ternative to the traditional treat- ment, transarterial chemoem- bolization (TACE). TACE com- bines anti- cancer drug therapy to shrink the tumor with emboliz- ing, or blocking, the hepatic artery that feeds the tumor. However, TACE requires a hos- pital stay of two to five days and can cause more damage to sur- rounding tissue than Thera- sphere. In addition, most pa- tients suffer post-embolization syndrome—a reaction to blood being cut off to a solid organ—as well as nausea, abdominal pain, ...

ASX/MEDIA RELEASE 15 th February 2005 Positive Phase IIa Trial Results in Liver Cancer BrachySil TM trial confirms safety and tumor regression in further patients Global nanotechnology company pSivida Limited ( NASDAQ:PSDV, ASX:PSD, Xetra:PSI ) is pleased to announce that its trial in inoperable primary liver cancer patients continues to show excellent results. Data from the second patient cohort of the current Phase IIa trial has further demonstrated that BrachySil™ (32-P BioSilicon™) is safe and effective in tumor regression with increased efficacy. Results of the second group of 4 patients, 12 weeks after their BrachySil™ treatment, revealed an average tumor regression by volume of 80% as determined by CT scanning. In some smaller tumors 100% regression was observed, a level of performance not seen with other intratumoral ...

ASX/MEDIA RELEASE 31 October 2005 BrachySil™ Phase IIb Clinical Trials for Liver Cancer Commence Following Approval by HSA First patient in multi-centre dose-profiling study receives treatment in Singapore General Hospital after approval by the Health Sciences Authority Global bio-nanotech company pSivida Limited (ASX:PSD, NASDAQ:PSDV, XETRA:PSI) is very pleased to announce that Phase IIb clinical trials have commenced with BrachySil™ (32-P BioSilicon™) as a potential new brachytherapy treatment for inoperable primary liver cancer (hepatocellular carcinoma, HCC). The first patient has successfully received treatment at Singapore General Hospital (“SGH”) using a new fine-gauge needle, multi-injection device which will enable for the first time, larger and also multiple tumors to be treated. A total of 50 patients will be entered into this multi-centre trial, which will be conducted ...

RISK FACTOR INFORMATION FOR SELECTED CANCER TYPES Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health March, 2005 206 Liver Cancer An estimated 17,550 people in the U.S. (12,130 men and 5,420 women) will be diagnosed with liver cancer in 2005, accounting for approximately 1% of all new cancers (ACS, 2005). Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver , accounting for about 75% of all cases. Rarer forms of malignant liver cancer include cholangiocarcinomas, angiosarcomas, and hepatoblastomas in children. Although HCC is approximately ten times more common in developing countries in East and Southeast Asia and Africa, incidence is rapidly increasing in the United States (ACS, 2001). Rates of HCC in the U.S. have increased by 70% over the past two decades (Yu et al., 2000). Similar trends have ...

Census Tract Total Males Females Obs Exp SIR Obs Exp SIR Obs Exp SIR 3543 3 1.8 NC NC -- NC 3 1.2 NC NC -- NC 0 0.7 NC NC -- NC 3546 2 1.7 NC NC -- NC 0 1.2 NC NC -- NC 2 0.6 NC NC -- NC 3549 4 1.8 NC NC -- NC 2 1.3 NC NC -- NC 2 0.5 NC NC -- NC City Total † 40 34.2 117 84 -- 159 26 23.9 109 71 -- 160 14 10.3 136 74 -- 227 † Cases for which census tract designation was not possible are included in the city total. Note: SIRs are calculated based on the exact number of expected cases. Expected number of cases presented are rounded to the nearest tenth. SIRs and 95% ...

National Cancer Institute SEER Program 68 LIVER AND INTRAHEPATIC BILE DUCT P rimary cancers of the liver and intrahepatic bile ducts are far more common in regions of Africa and Asia than in the United States, where they only account for about 1.5% of all cancer cases. Five-year survival rates are very low in the United States, usually less than 10%. Reported statistics for these cancers often include mortality rates that equal or exceed the incidence rates. This discrepancy (more deaths than cases) occurs when the cause of death is misclassified as “ liver cancer ” for some patients whose cancer originated as a primary cancer in another organ and spread (metastasized) to become a “secondary” cancer in the liver . Non-Hispanic white men and women have the lowest age-adjusted incidence rates (SEER areas) and mortality ...

A714-Test slide, Liver cancer tissues with corresponding normal tissues (formalin fixed) For research use only Specifications: • No. of cases: 6 • Tissue type: Test slide, Liver cancer tissues with corresponding normal tissues • No. of spots: 6 spots from each cancer case (6 spots) 6 non-neoplastic spots (6 spots) •Total spots: 12 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 A714-Test slide, Liver cancer tissues with corresponding normal tissues (formalin fixed) For research use only Summary of tissue spots No Sex Age Key word 1 A 1 m 67 Liver : ...

General facts of Liver cancer A913: Liver cancer There are two different types of primary liver cancer . The most common kind is called hepatoma or hepatocellular carcinoma (HCC), and arises from the main cells of the liver (the hepatocytes). This type is usually confined to the liver , although occasionally it spreads to other organs and occurs mostly in people with a liver disease called cirrhosis (see Causes section). There is also a rarer sub-type of hepatoma called Fibrolamellar hepatoma, which may occur in younger people and is not related to previous liver disease. The other type of primary liver cancer is called cholangiocarcinoma or bile duct cancer , because it starts in the cells lining the bile ducts. Some primary tumours in the liver are non-cancerous (benign) and do not spread to other parts of the body. They are usually small and may cause no symptoms, and are often ...